Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method

Archives of Pediatrics and Adolescent Medicine

Volumn 160, Issue 1, 2006, Pages 40-45

  Bonny, Andrea E ^a,b   Ziegler, Julie ^b   Harvey, Ray ^a,b   Debanne, Sara M ^a   Secic, Michelle ^c   Cromer, Barbara A ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

^c Secic Statistical Consultants   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEDROXYPROGESTERONE; ORAL CONTRACEPTIVE AGENT;

ADOLESCENCE; ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; BODY WEIGHT; CALCULATION; COHORT ANALYSIS; CONTRACEPTION; CONTROLLED STUDY; FEMALE; HEALTH CENTER; HEALTH VISITOR; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; OBESITY; PILL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SAMPLING; SCHOOL CHILD; STATISTICAL SIGNIFICANCE; URBAN AREA; WEIGHT GAIN;

ADOLESCENT; AMBULATORY CARE FACILITIES; ANALYSIS OF VARIANCE; BODY MASS INDEX; CASE-CONTROL STUDIES; CHILD; CONTRACEPTIVES, ORAL; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MEDROXYPROGESTERONE; OBESITY; PROSPECTIVE STUDIES; UNITED STATES; URBAN HEALTH SERVICES; WEIGHT GAIN;

EID: 29944435689     PISSN: 10724710     EISSN: 10724710     Source Type: Journal    
DOI: 10.1001/archpedi.160.1.40     Document Type: Article

References (25)

1. Harel Z, Biro FM, Kollar LM, Rauh JL. Adolescents' reasons for and experience after discontinuation of the long-acting contraceptives Depo-Provera and Norplant. J Adolesc Health. 1996;19:118-123.
2. O'Dell CM, Forke CM, Polaneczky MM, Sondheimer SJ, Slap GB. Depot medroxyprogesterone acetate or oral contraception in postpartum adolescents. Obstet Gynecol. 1998;91:609-614.
3. Polaneczky M, Liblanc M. Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents. J Adolesc Health. 1998;23:81-88.
4. Moore LL, Valuck R, McDougall C, Fink W. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Contraception. 1995;52:215-219.
5. Matson SC, Henderson KA, McGrath GJ. Physical findings and symptoms of depot medroxyprogesterone acetate use in adolescent females. J Pediatr Adolesc Gynecol. 1997;10:18-23.
6. Risser WL, Gefter LR, Barratt MS, Risser JM. Weight change in adolescents who used hormonal contraception. J Adolesc Health. 1999;24:433-436.
7. Mangan SA, Larsen PG, Hudson S. Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol. 2002;15:79-82.
8. Bonny AE, Britto MT, Huang B, Succop P, Slap GB. Weight gain, adiposity, and eating behaviors among adolescent females on depot medroxyprogesterone acetate (DMPA). J Pediatr Adolesc Gynecol. 2004;17:109-115.
9. Templeman C, Boyd H, Hertweck SP. Depomedroxyprogesterone acetate use and weight gain among adolescents. J Pediatr Adolesc Gynecol. 2000;13:45-46.
10. Speroff L, Andolsek K. Hormonal contraception and obesity. Dialogues Contracept. 2003;8:1-4.
11. Cromer BA, Binkovitz L, Ziegler J, Harvey R, Debanne SM. Reference values for bone mineral density in 12- to 18-year-old girls categorized by weight, race, and age. Pediatr Radiol. 2004;34:787-792.
12. Stadel BV, Sternthal PM, Schlesselman JJ, et al. Variation of ethinylestradiol blood levels among healthy women using oral contraceptives. Fertil Steril. 1980;33:257-260.
13. Holt VL, Cushing-Haugen KL, Daling JR. Body weight and risk of oral contraceptive failure. Obstet Gynecol. 2002;99(5 pt 1):820-827.
14. Holt VL, Scholes D, Wicklund KG, Cushing-Haugen KL, Daling JR. Body mass index, weight, and oral contraceptive failure risk. Obstet Gynecol. 2005;105:46-52.
15. Piccinino LJ, Mosher WD. Trends in contraceptive use in the United States: 1982-1995. Fam Plann Perspect. 1998;30:4-10, 46.
16. US Bureau of the Census. United States Census 2000 Summary File 1. Washington, DC: US Dept of Commerce, Economics and Statistics Administration; 2000.
17. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA. 2002;288:1728-1732.
18. Guthrie GP Jr, John WJ. The in vivo glucocorticoid and antiglucocorticoid actions of medroxyprogesterone acetate. Endocinology. 1980;107:1393-1396.
19. Fahmy K, Abdel-Razik M, Shaaraway M, et al. Effect of long-acting progestagenonly injectable contraceptives on carbohydrate metabolism and its hormonal profile. Contraception. 1991;44:419-430.
20. Ladisich W. Influence of progesterone on serotonin metabolism: a possible causal factor for mood changes. Psychoneuroendocrinology. 1977;2:257-266.
21. Koetsawang S, Shrimanker K, Fotherby K. Blood levels of medroxyprogesterone acetate after multiple injections of depoprovera or cycloprovera. Contraception. 1979;20:1-4.
22. Smit J, Botha J, McFadyen L, Beksinska M. Serum medroxyprogesterone acetate levels in new and repeat users of depot medroxyprogesterone acetate at the end of the dosing interval. Contraception. 2004;69:3-7.
23. Bassol S, Garza-Flores J, Cravioto MC, et al. Ovarian function following a single administration of depo-medroxyprogesterone acetate (DMPA) at different doses. Fertil Steril. 1984;42:216-222.
24. Ortiz A, Hirol M, Stanczyk FZ, Goebelsmann U, Mishell DR. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA. J Clin Endocrinol Metab. 1977;44:32-38.
25. Fotherby K, Saxena BN, Shrimanker K, et al. A preliminary pharmacokinetic and pharmacodynamic evaluation of depot-medroxyprogesterone acetate and norethisterone oenanthate. Fertil Steril. 1980;34:131-139.